- Home
- VERU vs TPST Comparison
VERU vs TPST Comparison
Compare VERU & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- TPST
- Stock Information
- Founded
- VERU 1971
- TPST 2011
- Country
- VERU United States
- TPST United States
- Employees
- VERU N/A
- TPST N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- TPST Health Care
- Exchange
- VERU Nasdaq
- TPST Nasdaq
- Market Cap
- VERU 54.6M
- TPST 45.5M
- IPO Year
- VERU 1990
- TPST N/A
- Fundamental
- Price
- VERU $3.75
- TPST $10.89
- Analyst Decision
- VERU Strong Buy
- TPST Hold
- Analyst Count
- VERU 3
- TPST 3
- Target Price
- VERU $33.33
- TPST $30.00
- AVG Volume (30 Days)
- VERU 139.0K
- TPST 44.6K
- Earning Date
- VERU 12-15-2025
- TPST 11-07-2025
- Dividend Yield
- VERU N/A
- TPST N/A
- EPS Growth
- VERU N/A
- TPST N/A
- EPS
- VERU N/A
- TPST N/A
- Revenue
- VERU $16,886,419.00
- TPST N/A
- Revenue This Year
- VERU N/A
- TPST N/A
- Revenue Next Year
- VERU N/A
- TPST N/A
- P/E Ratio
- VERU N/A
- TPST N/A
- Revenue Growth
- VERU 337.24
- TPST N/A
- 52 Week Low
- VERU $2.64
- TPST $5.35
- 52 Week High
- VERU $14.20
- TPST $15.73
- Technical
- Relative Strength Index (RSI)
- VERU 47.71
- TPST 54.09
- Support Level
- VERU $3.61
- TPST $10.09
- Resistance Level
- VERU $3.99
- TPST $11.13
- Average True Range (ATR)
- VERU 0.30
- TPST 0.68
- MACD
- VERU -0.10
- TPST -0.05
- Stochastic Oscillator
- VERU 14.52
- TPST 37.61
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.